Literature DB >> 33333774

Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.

Daniil Grinchii1, Eliyahu Dremencov1.   

Abstract

Atypical antipsychotic drugs were introduced in the early 1990s. Unlike typical antipsychotics, which are effective only against positive symptoms of schizophrenia, atypical antipsychotics are effective against negative and cognitive symptoms as well. Furthermore, they are effective not only in psychotic but also in affective disorders, on their own or as adjuncts to antidepressant drugs. This review presents the neural mechanisms of currently existing atypical antipsychotics and putative antipsychotics currently being investigated in preclinical and clinical studies and how these relate to their effectiveness in mood disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). Typical antipsychotics act almost exclusively on the dopamine system. Atypical drugs, however, modulate serotonin (5-HT), norepinephrine, and/or histamine neurotransmission as well. This multimodal mechanism of action putatively underlies the beneficial effect of atypical antipsychotics in mood and anxiety disorders. Interestingly, novel experimental drugs having dual antipsychotic and antidepressant therapeutic potential, such as histamine, adenosine, and trace amine-associated receptors (TAAR) ligand, are also characterized by a multimodal stimulatory effect on central 5-HT, norepinephrine, and/or histamine transmission. The multimodal stimulatory effect on central monoamine neurotransmission may be thus primarily responsible for the combined antidepressant and antipsychotic therapeutic potential of certain central nervous system (CNS) drugs.

Entities:  

Keywords:  adenosine; atypical antipsychotics; dopamine; histamine; mechanism of action; norepinephrine; receptor pharmacology; serotonin; trace amines

Mesh:

Substances:

Year:  2020        PMID: 33333774      PMCID: PMC7765178          DOI: 10.3390/ijms21249532

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   6.208


  93 in total

1.  Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum.

Authors:  Z Díaz-Cabiale; Y Hurd; D Guidolin; U B Finnman; M Zoli; L F Agnati; J J Vanderhaeghen; K Fuxe; S Ferré
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

2.  Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

Authors:  Eric J Lenze; Benoit H Mulsant; Daniel M Blumberger; Jordan F Karp; John W Newcomer; Stewart J Anderson; Mary Amanda Dew; Meryl A Butters; Jacqueline A Stack; Amy E Begley; Charles F Reynolds
Journal:  Lancet       Date:  2015-09-27       Impact factor: 79.321

3.  Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study.

Authors:  Gunnar Flik; Joost H A Folgering; Thomas I H F Cremers; Ben H C Westerink; Eliyahu Dremencov
Journal:  J Mol Neurosci       Date:  2015-03-29       Impact factor: 3.444

4.  Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.

Authors:  Soo-Kyung Kim; Peter Fristrup; Ravinder Abrol; William A Goddard
Journal:  J Chem Inf Model       Date:  2011-11-16       Impact factor: 4.956

Review 5.  Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders.

Authors:  Maria Rosaria Domenici; Antonella Ferrante; Alberto Martire; Valentina Chiodi; Rita Pepponi; Maria Teresa Tebano; Patrizia Popoli
Journal:  Pharmacol Res       Date:  2019-07-02       Impact factor: 7.658

6.  TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.

Authors:  Florent G Revel; Jean-Luc Moreau; Raul R Gainetdinov; Amyaouch Bradaia; Tatyana D Sotnikova; Roland Mory; Sean Durkin; Katrin Groebke Zbinden; Roger Norcross; Claas A Meyer; Veit Metzler; Sylvie Chaboz; Laurence Ozmen; Gerhard Trube; Bruno Pouzet; Bernhard Bettler; Marc G Caron; Joseph G Wettstein; Marius C Hoener
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-27       Impact factor: 11.205

Review 7.  Purinergic Signalling and Neurological Diseases: An Update.

Authors:  Geoffrey Burnstock
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

Review 8.  Aripiprazole alone or in combination for acute mania.

Authors:  Rachel Brown; Matthew J Taylor; John Geddes
Journal:  Cochrane Database Syst Rev       Date:  2013-12-17

9.  Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.

Authors:  Rajender R Aparasu; Elda Jano; Michael L Johnson; Hua Chen
Journal:  Am J Geriatr Pharmacother       Date:  2008-10

Review 10.  Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.

Authors:  Mostafa El Mansari; Bruno P Guiard; Olga Chernoloz; Ramez Ghanbari; Noam Katz; Pierre Blier
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

View more
  8 in total

Review 1.  Dopamine in Health and Disease: Much More Than a Neurotransmitter.

Authors:  Rafael Franco; Irene Reyes-Resina; Gemma Navarro
Journal:  Biomedicines       Date:  2021-01-22

Review 2.  Attractor cortical neurodynamics, schizophrenia, and depression.

Authors:  Edmund T Rolls
Journal:  Transl Psychiatry       Date:  2021-04-12       Impact factor: 6.222

3.  Intranasal delivery of Clozapine using nanoemulsion-based in-situ gels: An approach for bioavailability enhancement.

Authors:  Nourhan A Abdulla; Gehan F Balata; Hanaa A El-Ghamry; Eman Gomaa
Journal:  Saudi Pharm J       Date:  2021-11-15       Impact factor: 4.330

4.  Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.

Authors:  Bhanu Gupta; Kok-Seng Chee; Li-Qi Neo; Charmaine Tang; Jayaraman Hariram; Geoffrey Chern-Yee Tan; Swapna Verma; Sutapa Basu; Deva-Priya Appan; Chan-Chun Ting; Edimansyah Abdin; Jimmy Lee
Journal:  Ther Adv Psychopharmacol       Date:  2021-10-09

Review 5.  Microglia Involves in the Immune Inflammatory Response of Poststroke Depression: A Review of Evidence.

Authors:  Weili Xia; Yong Xu; Yuandong Gong; Xiaojing Cheng; Tiangui Yu; Gongchang Yu
Journal:  Oxid Med Cell Longev       Date:  2022-08-02       Impact factor: 7.310

6.  Effect of Haloperidol and Olanzapine on Hippocampal Cells' Proliferation in Animal Model of Schizophrenia.

Authors:  Jana Osacka; Alexander Kiss; Zuzana Bacova; Andrej Tillinger
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

7.  Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study.

Authors:  Essi Heinonen; Lisa Forsberg; Ulrika Nörby; Katarina Wide; Karin Källén
Journal:  BMJ Open       Date:  2022-06-29       Impact factor: 3.006

Review 8.  Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.

Authors:  Valeria Calsolaro; Grazia Daniela Femminella; Sara Rogani; Salvatore Esposito; Riccardo Franchi; Chukwuma Okoye; Giuseppe Rengo; Fabio Monzani
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.